• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to thiazolidinyl derivatives, in particular the substituted thiazolidinyl esters of phosphonic acid (TEF) of the general formula:,: - m, -C (0) -CHRj-SC NN C-SCHK-C (0) -N-CK.J ( 1), where K - 0-P (0) (OCH,), j; R, is allyl, 2-methylallyl, Rj-H or CH, which exhibit antitumor activity and can be used in medicine. The goal is to develop a new method of obtaining new TEFs. Synthesis of TEP is carried out from an alcohol of the corresponding thiazolidine and dimethylphosphoric acid halide in an inert solvent at a temperature of up to 50 ° C, mainly in the presence of a chloride acceptor yes, for example pyridine or trialkylamine, at 0-25 ° C. TEF tests show that they contribute to inhibition (up to 70%) of a tumor (breast carcinoma) with practically no toxicity (12,500 mg / kg). 1 hp f-ly, 4 tab. § (U) 00 00 O) 00 s
    公开号:SU1318168A3
    申请号:SU843740154
    申请日:1984-05-14
    公开日:1987-06-15
    发明作者:Сторни Анджело
    申请人:Циба-Гейси Аг (Фирма)；
    IPC主号:
    专利说明:


    . OC-N
    AND
    eleven
    This invention relates to the chemistry of organophosphorus compounds, namely to a process for the preparation of new substituted thiazolidinyl phosphoric acid esters of the general formula
    Shz
    -1 b1
    .Voctp o
    sc
    where R, is allyl or 2-methylallyl;
    R is hydrogen or methyl, possessing antitumor activity, which can be used in medicine.
    The aim of the invention is to develop a process for the preparation of substituted thiazolidinyl phosphoric acid esters with antitumor activity.
    Example. To a solution of 33 g (0.10 mol) of 5-ox.-3-methyl-2; 5-methyl-3- (2-methylallyl) -4-oxo-2-thiazolylidene-hydrazono; 4-thiazolidi- Nonna and 43 ml of ethyldiisopropylamine in 250 ml of methylene chloride are added dropwise with stirring 21 ml (0.2 mol) of dimethylphosphoric acid chloride. First, the reaction proceeds with a slight exothermic effect, and the reaction temperature is maintained at 25 ° C by cooling. After the addition is complete, the reaction mixture is further stirred for 2 hours at room temperature. After that, the reaction mixture is extracted first with 100 ml of ice-cold 2N hydrochloric acid and then with two portions of water, 100 ml each. The methylene chloride solution is dried over magnesium sulfate and evaporated in a water jet vacuum. In the form of a residue, dimethyl- 3-methyl 2- (5-methy-1-3- (2-methyl-10 10-oxo-2-thiazolidinylidene) -hydrazo-4-oxo-5-thiazolidinyl) phosphate is obtained; - thallization from diethyl ether melts at 103-104 C. The yield is 39.7 g (917.).
    Calculated,%: C 38.53; H 4.85; 12.84; P 7.10.
    S „N„ Y, OBRZg
    Found,%; C 38.48; H 4.81; 12.70; R 7.11.
    o
    five
    one
    five
    0
    35 0 5 0
    five
    68
    Example2. To a suspension of 30 g (0.10 mol) of 2- (3-allyl-4-oxo-2-thiazolidinylidene) -hydrazono-5-hydroxy-3-methyl-4-thiazolidinone and 21.7 g (0.15 mole) of dimethylphosphoric acid hporanhydride in 250 ml of methylene chloride with stirring and a temperature of 5-10 ° C is added dropwise 16.7 ml (0.12 mol) of triethylamine. The reaction proceeds with a slight exothermic effect, and the suspended substances, with the exception of the triethylamine hydrochloride formed, are dissolved. After the addition is complete, the reaction mixture is further stirred for 1 hour at room temperature. After that, the reaction mixture is extracted first with 200 ml of ice-cold water and then 100 ml of ice-cooled saturated sodium hydrogen carbonate solution. The methylene chloride solution is dried over magnesium sulphate and evaporated under reduced pressure until the product starts to crystallize. The residue is mixed with 100 ml of diethyl ether, after which 2- - (3-allyl-4-oxo-2-thiazolidinsidine) - gi, crazono-3-methyl-4-oxo-5-thiazoles are separated by suction filtering. - dinyl-dimethyl phosphate, with so pl. 147-148 ° C. Yield 35.0 g (85.7%).
    Calculated,%: C 35.30; H 4.20; N 13.72; R 7.59. C ,, H ,, N, 0, PS ,,
    Found,%: C 35.28; H 4.20; 13.81; R 7.63.
    The original substance can be obtained as follows:
    a) 17.1 g (0.10 mol) of 3-allyl-2,4-thiazolidinedione-2-hydrazone (colorless oily substance) and 8.0 g (0.11 mol) of methyl isothiocyanate are heated for 2 hours stirring in 70 ml of isopropyl alcohol at 80 ° C; boiling point of the reaction mixture under reflux, and 3-allyl-2,4-thiazolidinedione-2- (4-methyl-3-thiosemicarbazone) is released as a large crystalline precipitate. The reaction mixture is cooled with ice, the product is filtered on a suction filter and washed with a mixture of pentane and diethyl ether in a ratio of 1: 1. M.p. 148-15l C.
    b). 11.0 g (0.12 mol of glyoxylic acid monohydrate is dissolved in 40 ml of dioxaia and directly
    31
    thereafter, the solution is diluted with 200 X carbon tetrachloride. Then, 24.4 g (0.10 mol) of 3-allyl-2,4-ty azolidinedione-2-4-methyl-3-thiosemicarbazone was added to the solution with stirring. After that, the mixture is heated and, while adding 120 ml of carbon tetrachloride dropwise through a descending cooler, 120 ml of the azeotropic mixture of carbon tetrachloride and water is distilled off. The reaction mixture is then cooled to 20 ° C, the crystal mass is diluted with 100 ml of diethyl ether, filtered off on the suction filter and wash with diethyl ether. The resulting 2- (3-allyl-4-oxo-2-thiazolidinylidene) -hydrazono-5-hydroxy-3-methyl-4-thiazolidinone has mp 209-210 C.
    Example In Example 2, 2- (3-allyl-5-methyl-4-oxo-2-thiazolidinylidene) -hydrazono-3-methyl 4-oxo-5-thiazolidinyl 1-dimethylphosO J is prepared.
    veil with so-called 106-107 C, when used as starting compounds
    31.4g (0.10 mol) of 2- (3-allyl-5-methyl-4-ox-2-thiazolylidene) -hydro-5-hydroxy-3-methyl-4-thiazolidinone, 21, 7 g (0.15 mol) of dimethylphosphoric acid chloride and 16.7 ml (0.12 mol) of triethylamine in
    250 MP methylene chloride. Output
    36.5g (86.4%).
    Calculated,%: C 36.96; H 4.53; N 13.26; R 7.33.
    C ,, H ,, N, 0, PS
    Found,%: C 37.00; H 4.55; N 13.21; R 7.37.
    The starting material can be obtained as follows.
    11.0 g (0.12 mol) of glyoxylic acid monohydrate is dissolved in 40 ml of dioxane and immediately after this the solution is diluted with the addition of 200 ml of carbon tetrachloride. Then, with stirring, 25.8 g (0.10 mol of 3-allyl-5-methyl-2,4-Thiazolidinedione-2- (4-methyl-3-thiosemicarbazone) is added to the solution. The reaction mixture is then heated and at the same time 120 ml of carbon tetrachloride are added dropwise through a descending cooler. 120 ml of azeotropic mixture of four-chloride carbon and water are distilled off. The reaction mixture is cooled to 20 ° C, the crystal mass is diluted with 100 ml of diethyl ether and 200 ml
    five
    eight
    five
    0
    about

    five
    five
    0
    684
    pentane, the crystalline product is separated by filtration on a suction filter and washed with a mixture of pentane and diethyl ether in a ratio of 2: 1. 2- (3-allyl-5-methyl-4-ox-6-thiazolidinylidene) -hydrazono-5-hydroxy-3-methyl-4-thiazolidinone is m.p. 164-16b.
    Example 4. To a solution of 30 g (0.10 mol) of 2- (3-allyl-4-oxo-2-thiazolidinylidene) -hydrazono | -5-hydroxy-3-methyl-4-thiazolidinone in 200 ml of acetonitrile 17.4 g (0.12 mol) of dimethylphosphoric acid chloride are added dropwise. The reaction mixture is mixed for 1 hour at 50 ° C, then cooled and poured into 600 ml of methylene chloride. The reaction mixture is then extracted first with 200 ml of ice-cold water and then twice with 100 ml of ice-cold saturated sodium hydrogen carbonate solution. Methylene chloride solution of supta over magnesium sulphate and under reduced pressure is evaporated to 100 ml of product. The precipitate is mixed with 200 ml of diethyl ether and the resulting dimethyl- (3-allyl-4-oxo-2-thiazolidinylidene) -l idrazono-3-methyl-4-oxo-5-thiazolidine | -phosphate, which has m.p. 46-148 ° C. Yield 35.9 g (88%).
    Example5. To a suspension of 31.4 g (0.10 mol) of 2- (3-allyl-5-methyl-4-oxo-2-thiazolidinylidene) -hydrazono-5-hydroxy-3-metsh-4-thiazolidinone in 250 ml of methylene chloride while stirring at a temperature of 0 ° C, 28.4 g (0.15 mol) of dimethylphosphoric acid bromide is added dropwise and then 16.7 ml (0.12 mol) of triethylamine is slowly added dropwise. The reaction mixture is further stirred at 0 ° C and first extracted with 200 ml of ice-cold water and then 100 ml of ice-cooled saturated sodium hydrogen carbonate solution. The methylene chloride solution is dried over magnesium sulphate and evaporated under reduced pressure until the product starts to crystallize. Then 100 ml of diethyl ether are added and the dimethyl -2- (3-allyl-5-metsh-4-oxo-2-thiazolidinylidene) -hydrazono-3-methyl-4-oxo-5-thiazolidinyl | -phosphate is filtered off. which has a mp. 106-107 s. The yield of 38.2 g (90.4%).
    five
    The described compounds of formula I have the ability to inhibit the development of tumors. This effect was found in animal experiments, for example, on the effect on Ehrlich carcinoma in mice (graft - 1 x 0 Ascites i.p. cells on female NMRI mice) with the administration of po, i.p., or S.C. at a dose of 10–250 mg / kg, for effects on carcinosarcoma 256 Walters in rats (transplant 0.5 ml of tumor suspension in Hanks SC solution or im in the case of male Wistar rats), for effects on R3230 AC transplant breast adenocarcinoma in rats (graft - 0.5 MP of a suspension of a tumor in a solution of Hanks sc or im in the case of female Fischer rats) and, in particular, on the effects on the breast carcinoma in rats, caused by 7.12 - dimethylbenz | 3 (. anthracene ( DMBA) by administering ro. 15 mg DMBA in 1 m of sesame oil in female Sprague Dawley rats aged 50 s t, wherein overgrown with tumor can be detected after 6-8 weeks.
    Thus, for example, the compound obtained according to example 1 in the case of Ehrlich carcinoma after four administrations of 100 mg / kg i.p. (after 4 hours, then after 1.2 and 3 days after transplantation, 10 animals per dose, 10 days after transplantation, the number of Ascites cells per milliliter and, in the case of carcinosarcoma 256 Walker, after four times the p or o (100 mg / kg; 1,2,3 and 4 days after transplantation. 8-10 animals per dose, 10 days after transplantation determine the weight of the tumor in grams) inhibits the development of tumors 70 and 53%, respectively
    In the case of breast carcinoma induced by DMBA, 90% growth inhibition or reduction of tumors was found after five weeks (25 individual doses of 100 mg / kg po) or six weeks (30 individual doses) of treatment, with all tumors in all experimental animals 2 , 13 and 21.55 cm (treated and untreated animals, respectively).
    Data on antitumor activity in relation to Ehrlich carcinoma in menspei dimethyl-3-metsh-2- (5-methyl-3 (2-mets allyl) 4-oxo-2-thiazo 686
    lidinylidene-hydrazono-4-oxo-5-thiazolidinyl | -phosphate (A, compound prepared according to example 1) and 2-C (3-allyl-4-oxo-2-thiazolidine lidene) -hydrazono-3-methyl- 4-oxo-5-thiazolidinyl-dimethyl phosphate (B, Example 2) in comparison with 5-hydroxy-3-methyl 2 5-methyl-3- (2-methylallyl) -4-oxo 2-thiazolidinyl-hydrazono-4- thiazolidinone (C), the closest in structure to a known compound, is presented in Table 1.
    Spreadsheets
    a 1
    Compared with high antitumor activity, toxicity and side effects of the described compounds of formula I are insignificant.
    Table 2 presents the maximum allowable doses for children in the case of
    single dose,
    40
    Table 2
    55
    The described compounds of the formula D are chemically stable and have a high water solubility, therefore, they can be used both as enteral and parenteral preparations.
    7
    权利要求:
    Claims (2)
    [1]
    1. A process for the preparation of substituted thiazolidinyl phosphoric acid esters of the general formula
    Cft
    N-CO I I -N
    -N C-o-C r /
    OSSN
    DOS
    whether 2-methylallyl; or methyl, that compound
    Editor I.Rybchenko
    Compiled by M.Krasnovska
    Tehred I. Morgental Corrector L. Patay
    Order 2441/58 Circulation 347Subscription
    VNIIPI USSR State Committee
    for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
    Production and printing company, Uzhgorod, Projecto st., 4
    RI
    Cn
    HE
    cv-fc
    3
    N-co
    I n N-lSl Cv-Cr
    HE
    where RJ and R have the indicated meanings, they are reacted with dimethylphosphoric acid halide in an inert organic solvent medium when heated to 50 ° C.
    [2]
    2. The method according to claim 1, namely, the interaction is carried out
    in the presence of a hydrogen chloride acceptor, for example, pyridine or tri-lower alkylamine at 0-25 C.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0350002B1|1993-01-13|Diphosphonic-acid derivatives, process for their preparation and medicines containing those compounds
    KR0147830B1|1998-08-17|Phenol substituted gem-disphosphonate derivatives, process for their preparation and pharmaceutical ceutical composition coutaining t
    KR930005390B1|1993-06-19|Process for producing 2-substituted-1,3-propylidenedipho sphonate derivatives
    EP0376518A1|1990-07-04|Phospholipid nucleosides
    SU514569A3|1976-05-15|The method of producing pyridazine derivatives
    SU1318168A3|1987-06-15|Method for producing substituted thiazolidinyl esters of phosphoric acid
    SU1739845A3|1992-06-07|Method for synthesis of isoindolinone derivatives or their salts
    RU2042659C1|1995-08-27|Method of synthesis of 1-aryl-2-arylhydroxyethane derivatives
    JPH0751587B2|1995-06-05|Phospholipid derivative
    SU1342415A3|1987-09-30|Method of producing derivatives of pyridazine
    SU498912A3|1976-01-05|The method of obtaining triazolothiazole esters of phosphorus acids
    US4309412A|1982-01-05|Germanium-containing organic polymer and its use in the treatment of liver disorders
    Maier1973|Organic Phosphorus Compounds 60. The direct synthesis of tris | phosphine oxides
    SU1017171A3|1983-05-07|Process for preparing derivatives of pyrazolo |quinazoline or their salts
    EA001959B1|2001-10-22|New pentaerythritol derivatives, their production and use and intermediatesfor their synthesis
    US4129660A|1978-12-12|Derivatives of cis-epoxy-1,2-propyl-phosphonic acid and drugs containing in particular as active ingredients derivatives of cis-epoxy-1,2-propylphosphonic acid in dextrorotatory form
    EP0313997B1|1994-03-09|Medicine, therein contained phosphor containing 2-isoxazolidines and isoxazoles, as well as process for preparing those heterocyclic compounds
    US3940423A|1976-02-24|1,2-O-dialkylmethylidene-glycero-3-phosphatides
    US2746967A|1956-05-22|Derivatives of bis-| alkanes
    JP2997552B2|2000-01-11|2-Formylbenzylphosphonic acid derivative and method for producing the same
    FI66856C|1984-12-10|FRAMEWORK FOR FRAMSTAELLNING AV NYA HJAERTSTIMULERANDE ALKANOLAMINDERIVAT
    PT93675B|1996-08-30|PROCESS FOR THE PREPARATION OF DERIVATIVES OF UNATURATED AMINODYCARBOXYL ACIDS, CONTAINING PHOSPHORUS
    SU582741A3|1977-11-30|Insecticide
    US4267172A|1981-05-12|Bis| phosphites
    RU2135502C1|1999-08-27|Clavulanic acid diamine salts, method of their synthesis |, method of synthesis of clavulanic acid or its pharmaceutically acceptable salt, method of purification of clavulanic acid of its salt
    同族专利:
    公开号 | 公开日
    JPS58135871A|1983-08-12|
    FI823458A0|1982-10-11|
    EP0085275B1|1986-02-19|
    NO823445L|1983-07-25|
    IL67023D0|1983-02-23|
    PL238799A1|1984-02-27|
    ES8603439A1|1985-12-16|
    ZA827444B|1983-08-31|
    GB2122604A|1984-01-18|
    ES8605512A1|1986-03-16|
    RO85276A|1984-09-29|
    PL137949B1|1986-08-30|
    CS241514B2|1986-03-13|
    PT75704B|1985-12-03|
    CS742082A2|1985-08-15|
    RO85276B|1984-10-30|
    SU1181545A3|1985-09-23|
    KR880001716B1|1988-09-08|
    AT18044T|1986-03-15|
    PL138373B1|1986-09-30|
    GR77024B|1984-09-04|
    ES516888A0|1985-07-16|
    PH20238A|1986-10-10|
    AU8938982A|1983-07-28|
    ES8506706A1|1985-07-16|
    KR840001998A|1984-06-11|
    DE3269209D1|1986-03-27|
    US4489069A|1984-12-18|
    AU555533B2|1986-10-02|
    IL67023A|1986-07-31|
    DK451282A|1983-07-23|
    HU188214B|1986-03-28|
    ES535201A0|1985-12-16|
    DD203909A5|1983-11-09|
    RO87991A|1985-11-30|
    RO87991B|1985-10-31|
    PL244185A1|1984-05-21|
    GB2122604B|1986-01-08|
    NZ202179A|1986-04-11|
    SU1384202A3|1988-03-23|
    PT75704A|1982-11-01|
    EP0085275A1|1983-08-10|
    ES529335A0|1986-03-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3699116A|1965-10-29|1972-10-17|Ciba Geigy Corp|2,2'-azines of 2,4-thiazolidinediones|
    AR204619A1|1973-02-13|1976-02-20|Ciba Geigy Ag|PROCEDURE FOR THE PREPARATION OF A NEW DERIVATIVE OF 2,2-AZINE-2,4-THIAZOLIDINDIONA|
    DE2632746A1|1975-08-06|1977-02-24|Ciba Geigy Ag|Tumour-inhibiting bis-thiazolidine azines - with methyl substits. at 5-position, and their Mannich base precursors|
    DE3002733A1|1979-01-29|1980-08-07|Ciba Geigy Ag|Insecticide, acaricide 4-alkyl-2-thiazolyl phosphate derivs. - prepd. by reacting a 4-alkyl-2-hydroxy-thiazole with a phosphoryl, thio-phosphoryl or di:thio-phosphoryl halide|US4582841A|1983-07-19|1986-04-15|Ciba-Geigy Corporation|Substituted thiazolidinyl esters of mineral acids|
    WO1986007360A1|1985-06-10|1986-12-18|Ciba-Geigy Ag|Substituted thiazolidinyl ether|
    ZA868951B|1985-12-07|1987-08-26|Shionogi & Company Limited|Organophosphorus compounds having pesticidal activity|
    US5177091A|1990-12-06|1993-01-05|Ciba-Geigy Corporation|Use of carbazones as novel active ingredients in medicaments|
    AU658175B2|1991-04-12|1995-04-06|Novartis Ag|Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients|
    AU665073B2|1992-06-03|1995-12-14|Ciba-Geigy Ag|Novel thiosemicarbazone derivatives|
    JPH09511334A|1994-03-30|1997-11-11|チバ−ガイギーアクチェンゲゼルシャフト|Screening method using RZR receptor family|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    CH40682|1982-01-22|
    [返回顶部]